A
Acticor Biotech
Biotech & Life Sciences · Paris, France · Founded 2013
Safe and effective treatment of stroke MoreLess
Acticor Biotech is a clinical-stage biotechnology company focused on developing innovative treatments for acute thrombotic diseases, particularly acute ischemic stroke. Founded in 2013 as a spin-off from INSERM, the company leverages academic research to create therapeutic monoclonal antibodies. Acticor Biotech's primary drug candidate, Glenzocimab, is designed to inhibit glycoprotein VI, a key player in collagen-induced platelet aggregation, which is crucial in the formation of blood clots. The company has successfully completed the first phase of its ACTIMIS study, demonstrating promising results in patients with acute ischemic stroke.
Acticor Biotech operates in the biopharmaceutical market, targeting healthcare providers and patients affected by stroke and other thrombotic conditions. The business model revolves around the development, clinical testing, and eventual commercialization of its drug candidates. Revenue is primarily generated through partnerships, licensing agreements, and future sales of approved treatments.
Keywords: biotechnology, stroke treatment, monoclonal antibodies, Glenzocimab, thrombotic diseases, clinical-stage, biopharmaceutical, acute ischemic stroke, drug development, healthcare.
Company overview
Acticor Biotech company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2013
- Headquarters
- Paris, France
- Employees
- 8
- Open positions
- None listed
- Dealroom signal
- 60.2
Valuation & funding
Acticor Biotech funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Nov 2019 | $7.7M | $31M | Newton BioCapital · Anaxago · Karista · GO Capital | — |
| SERIES B✓Equity / VC | Oct 2018 | $17M | $67M | Primer Capital · Mirae Asset Capital · Karista · Newton BioCapital | ↗ |
| GRANT✓Other financing | Jan 2018 | $2.4M | — | Bpifrance | — |
| SERIES A✓Equity / VC | Jan 2018 | $1.9M | $7.5M | Karista · Primer Capital · Anaxago | ↗ |
| EARLY VC✓Equity / VC | Feb 2017 | $1.6M | $6.6M | Karista | ↗ |
| EARLY VC✓Equity / VC | Jul 2016 | Anaxago | — | ||
| SPINOUT✓Other financing | Jan 2013 | CNRS Innovation · Ouest Valorisation · French National Centre for Scientific Research - CNRS · University of Western Brittany | — | ||
| SUPPORT PROGRAM✓Other financing | Jan 2013 | Ouest Valorisation | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
Growth signals
Acticor Biotech website traffic
Latest recorded traffic for Acticor Biotech is 680 monthly website visits, up 423.1% over the last three months. Acticor Biotech's team declined 33.3% over the past year.
Comparisons
Acticor Biotech compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Acticor Biotech's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Acticor Biotech has talent and traffic
team presence
In the news
Latest news about Acticor Biotech
Recent press, funding announcements, and product moves mentioning Acticor Biotech — open to read from the original sources.
Market sentiment
What the market is saying about Acticor Biotech
An AI-synthesized read of the highest-engagement posts about Acticor Biotech on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Acticor Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.